Next Phase Newsletter

An innovation center established by an international health care company is dedicated to advancing technologies/products/services that can improve life of people living with psoriasis and other dermatology conditions. The firm can acquire assets/companies outright or provide equity financing, but prefers to partner with companies to co-develop the technology, whether that be through one-off projects to evaluate the feasibility of the technology in a dermatology application or joint ventures. Along with capital, it also supports the company with access to patient population and a network of dermatologists and HCP’s. The firm places a strong emphasis on impacting patient’s lives. The firm will work with companies who are headquartered in, or plan to expand into, North America, Canada the United Kingdom or France.

The firm is focused on finding solutions “beyond the pill” for people living with a variety of dermatology conditions, with a particular focus on psoriasis and bridging the gap between digital and physical solutions. Current efforts are focused on psoriasis in particular, but will consider other technologies with applications in other dermatology indications. The company is not involved in traditional therapies in terms of therapeutics and/or medical devices, but rather any technology that can be used to improve the lives of psoriasis patients. These technologies could include wearables, connected devices, sensors, telemedicine, etc. that have applications in dermatology indications, preferably psoriasis. In addition, technologies in the wellness space that are relevant to patients are also a strong focus – nutrition, fitness, stress management, mental health, beauty, etc.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices in Canada and the US is making investments out of its vintage 2016, fourth fund and is exclusively focused on advanced materials.  The firm typically makes initial investments in the $1M-$5M range and up to $10M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. With strategic LP relationships in Asia, Europe and the Middle East, the firm is open to companies globally and looks to make 3-4 new investments per year.

The firm’s primary investment thesis is technology driven, breakthrough IP. Within healthcare, the firm is interested in medical devices and diagnostics whose underlying value is in the material as well as advanced materials with antibacterial properties and the like. The firm does not make investments in pharmaceuticals/therapeutics of any kind.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A fund headquartered in San Francisco is investing from its most recent fund, which closed in late 2015 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations fall between $0.1 M-$2 M. The three main areas of interest for the firm are enterprise software, smart hardware, and data-driven healthcare. They will look at deals globally, but tend to focus on companies headquartered in North America.

The sectors of interest for the firm span medical technology, healthcare IT, suppliers and engineering, R&D services, and diagnostics. The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, virtual reality, robotics, and machine learning are of interest. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience in the market they are targeting. They are a passive investor, and do not usually seek a board seat but may if their background lends expertise to the venture.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A medical products corporation headquartered in Europe is focused on flexible endoscopy for gastroenterology and urology as well as hospital supplies. The firm is seeking to in-license approved or close-to-approval products from across the globe; growth capital investment would also be considered. Currently the firm is interested in products with large potential in EU and Asia markets.

For in-licensing opportunities, the firm is focused on gastroenterology and urology, including bladder, kidney, prostate, and incontinence illnesses. The firm considers therapeutic devices and diagnostic tools, mainly for flexible endoscopy. The firm is most interested in products that have received or are close to receiving regulatory approval such as a CE mark.

The firm is looking for experienced management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An NJ-based venture investment firm focused on bridging Eastern and Western innovations and investment opportunities invests in early to mid-stage biopharma and medtech projects. With its own R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be a consideration for their investment opportunities. With additional strategic investing partners in China, the size of investment can vary depending on the deal. The firm is currently looking for new opportunities globally.

The firm is interested in preclinical to phase 1/2 stage assets in biotech and medtech. The firm is open to all therapeutic modalities. Within medtech, the firm is more interested in personalized medicine/companion diagnostics and novel devices. In terms of disease areas, the firm is most interested in chronic diseases, liver and gastrointestinal conditions, but the firm generally avoids behavioral illnesses.

The firm is seeking strong management teams with products that could address large unmet medical need. The firm has R&D facilities in China that can facilitate product development and registration both for China local and global market. The firm is open to negotiate regional rights with flexible terms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture fund headquartered in Cambridge, MA makes Series A-stage investments of $200 K – $500 K. Follow on funding is coordinated through syndication and can range from $0.5 – 5 M. The firm focuses on the healthcare IT, digital health, and suppliers and engineering sectors, and prefers companies located in the US. Companies should be in the early stages of revenue production and exhibit some market traction and potential for global expansion. The firm will make about 6 new investments over the next 12 months.

The firm looks for enterprise technology plays that incorporate proprietary algorithms for data mining, machine learning, connected devices, virtual reality, and other technologies to create new systems. Past investments include biomedical and genomics data analytics platforms. They would consider wearable or medical devices that incorporate sophisticated software or connectivity.

The firm seeks experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Initial revenue generation and evidence of market strength is desired.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global pharmaceutical company invests to further its’ parent company’s future strategic position, rather than purely for financial returns.  The firm looks to make equity investments into emerging biotech and pharmaceutical companies ranging from a few hundred thousand to $6 million in the initial round, with additional capital reserved for follow on investments. The firm has no set allocations it plans to make over the next year but is actively reviewing new opportunities. The firm considers opportunities located around the globe.

The firm is looking for biopharmaceutical companies developing therapeutics and therapeutic platforms at any stage of development and is open to considering both small molecules, biologics, nucleic acid, and gene and cellular therapeutic approaches. The firm is interested in immunology, neuroscience, oncology as well as other opportunistic areas that can benefit its parent company.

The firm is looking for companies with experienced management teams with domain expertise. The firm strongly prefers board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com